133 related articles for article (PubMed ID: 37334764)
1. The Ranger drug-coated balloon: advances in drug-coated technology for treatment of femoropopliteal segment arterial disease.
Sharma N; Finn MT; Parikh SA; Granada J
Future Cardiol; 2023 Mar; 19(3):127-135. PubMed ID: 37334764
[TBL] [Abstract][Full Text] [Related]
2. 12-Month Results From the First-in-Human Randomized Study of the Ranger Paclitaxel-Coated Balloon for Femoropopliteal Treatment.
Steiner S; Willfort-Ehringer A; Sievert H; Geist V; Lichtenberg M; Del Giudice C; Sauguet A; Diaz-Cartelle J; Marx C; Ströbel A; Schult I; Scheinert D;
JACC Cardiovasc Interv; 2018 May; 11(10):934-941. PubMed ID: 29730375
[TBL] [Abstract][Full Text] [Related]
3. Six-Month Results From the Initial Randomized Study of the Ranger Paclitaxel-Coated Balloon in the Femoropopliteal Segment.
Bausback Y; Willfort-Ehringer A; Sievert H; Geist V; Lichtenberg M; Del Giudice C; Sauguet A; Diaz-Cartelle J; Marx C; Ströbel A; Schult I; Scheinert D;
J Endovasc Ther; 2017 Aug; 24(4):459-467. PubMed ID: 28558502
[TBL] [Abstract][Full Text] [Related]
4. Systematic review and updated meta-analysis of the use of drug-coated balloon angioplasty versus plain old balloon angioplasty for femoropopliteal arterial disease.
Caradu C; Lakhlifi E; Colacchio EC; Midy D; Bérard X; Poirier M; Ducasse E
J Vasc Surg; 2019 Sep; 70(3):981-995.e10. PubMed ID: 31126769
[TBL] [Abstract][Full Text] [Related]
5. Stellarex Drug-Coated Balloon for Treatment of Femoropopliteal Disease: Twelve-Month Outcomes From the Randomized ILLUMENATE Pivotal and Pharmacokinetic Studies.
Krishnan P; Faries P; Niazi K; Jain A; Sachar R; Bachinsky WB; Cardenas J; Werner M; Brodmann M; Mustapha JA; Mena-Hurtado C; Jaff MR; Holden AH; Lyden SP
Circulation; 2017 Sep; 136(12):1102-1113. PubMed ID: 28729250
[TBL] [Abstract][Full Text] [Related]
6. 1-Year Results From the RANGER II SFA Randomized Trial of the Ranger Drug-Coated Balloon.
Sachar R; Soga Y; Ansari MM; Kozuki A; Lopez L; Brodmann M; Schroë H; Ramanath VS; Diaz-Cartelle J; Zeller T;
JACC Cardiovasc Interv; 2021 May; 14(10):1123-1133. PubMed ID: 34016410
[TBL] [Abstract][Full Text] [Related]
7. Low-Dose Paclitaxel-Coated Versus Uncoated Percutaneous Transluminal Balloon Angioplasty for Femoropopliteal Peripheral Artery Disease: One-Year Results of the ILLUMENATE European Randomized Clinical Trial (Randomized Trial of a Novel Paclitaxel-Coated Percutaneous Angioplasty Balloon).
Schroeder H; Werner M; Meyer DR; Reimer P; Krüger K; Jaff MR; Brodmann M;
Circulation; 2017 Jun; 135(23):2227-2236. PubMed ID: 28424223
[TBL] [Abstract][Full Text] [Related]
8. Drug-coated balloons to improve femoropopliteal artery patency: Rationale and design of the LEVANT 2 trial.
Jaff MR; Rosenfield K; Scheinert D; Rocha-Singh K; Benenati J; Nehler M; White CJ
Am Heart J; 2015 Apr; 169(4):479-85. PubMed ID: 25819854
[TBL] [Abstract][Full Text] [Related]
9. Paclitaxel-Coated Balloon vs Uncoated Balloon Angioplasty for Treatment of In-Stent Restenosis in the Superficial Femoral and Popliteal Arteries: The COPA CABANA Trial.
Tepe G; Schroeder H; Albrecht T; Reimer P; Diehm N; Baeriswyl JL; Brechtel K; Speck U; Zeller T
J Endovasc Ther; 2020 Apr; 27(2):276-286. PubMed ID: 32096451
[No Abstract] [Full Text] [Related]
10. Low-Dose vs High-Dose Drug-Coated Balloon for Symptomatic Femoropopliteal Artery Disease: The PROSPECT MONSTER Study Outcomes.
Nakama T; Takahara M; Iwata Y; Suzuki K; Tobita K; Hayakawa N; Horie K; Mori S; Obunai K; Ohki T;
JACC Cardiovasc Interv; 2023 Nov; 16(21):2655-2665. PubMed ID: 37804292
[TBL] [Abstract][Full Text] [Related]
11. Safety of Paclitaxel-Coated Balloon Angioplasty for Femoropopliteal Peripheral Artery Disease.
Ouriel K; Adelman MA; Rosenfield K; Scheinert D; Brodmann M; Peña C; Geraghty P; Lee A; White R; Clair DG
JACC Cardiovasc Interv; 2019 Dec; 12(24):2515-2524. PubMed ID: 31575518
[TBL] [Abstract][Full Text] [Related]
12. Assessment of Sirolimus- vs. paCLitaxEl-coated balloon angioPlasty In atherosclerotic femoropopliteal lesiOnS (ASCLEPIOS Study): preliminary results.
Taneva GT; Pitoulias GA; Abu Bakr N; Kazemtash M; Muñoz Castellanos J; Donas KP
J Cardiovasc Surg (Torino); 2022 Feb; 63(1):8-12. PubMed ID: 35179337
[TBL] [Abstract][Full Text] [Related]
13. Health Care Utilization Following Inpatient Femoropopliteal Revascularization With Drug-Coated Balloon Angioplasty: A Nationwide Cohort Analysis.
Gurin MI; Beyer SE; Weinberg M; Parikh SA; Armstrong EJ; Albaghdadi MS; Aronow HD; Carroll BJ; Yeh R; Secemsky EA
J Endovasc Ther; 2021 Apr; 28(2):246-254. PubMed ID: 33426984
[TBL] [Abstract][Full Text] [Related]
14. An Experimental Study of Paclitaxel Embolisation During Drug Coated Balloon Angioplasty.
Boitet A; Grassin-Delyle S; Louedec L; Dupont S; Lamy E; Coggia M; Michel JB; Coscas R
Eur J Vasc Endovasc Surg; 2019 Apr; 57(4):578-586. PubMed ID: 30871939
[TBL] [Abstract][Full Text] [Related]
15. The LEVANT I (Lutonix paclitaxel-coated balloon for the prevention of femoropopliteal restenosis) trial for femoropopliteal revascularization: first-in-human randomized trial of low-dose drug-coated balloon versus uncoated balloon angioplasty.
Scheinert D; Duda S; Zeller T; Krankenberg H; Ricke J; Bosiers M; Tepe G; Naisbitt S; Rosenfield K
JACC Cardiovasc Interv; 2014 Jan; 7(1):10-9. PubMed ID: 24456716
[TBL] [Abstract][Full Text] [Related]
16. Development of drug-coated balloon for the treatment of multiple peripheral artery segments.
Anderson JA; Lamichhane S; Fuglsby K; Remund T; Pohlson K; Evans R; Engebretson D; Kelly P
J Vasc Surg; 2020 May; 71(5):1750-1757.e7. PubMed ID: 31519510
[TBL] [Abstract][Full Text] [Related]
17. Treatment Effect of Drug-Coated Balloons Is Durable to 3 Years in the Femoropopliteal Arteries: Long-Term Results of the IN.PACT SFA Randomized Trial.
Schneider PA; Laird JR; Tepe G; Brodmann M; Zeller T; Scheinert D; Metzger C; Micari A; Sachar R; Jaff MR; Wang H; Hasenbank MS; Krishnan P;
Circ Cardiovasc Interv; 2018 Jan; 11(1):e005891. PubMed ID: 29326153
[TBL] [Abstract][Full Text] [Related]
18. Critical appraisal of paclitaxel balloon angioplasty for femoral-popliteal arterial disease.
Herten M; Torsello GB; Schönefeld E; Stahlhoff S
Vasc Health Risk Manag; 2016; 12():341-56. PubMed ID: 27621646
[TBL] [Abstract][Full Text] [Related]
19. Head-to-head comparison of sirolimus- versus paclitaxel-coated balloon angioplasty in the femoropopliteal artery: study protocol for the randomized controlled SIRONA trial.
Teichgräber U; Ingwersen M; Platzer S; Lehmann T; Zeller T; Aschenbach R; Scheinert D
Trials; 2021 Sep; 22(1):665. PubMed ID: 34583746
[TBL] [Abstract][Full Text] [Related]
20. Long-Term Clinical Effectiveness of a Drug-Coated Balloon for the Treatment of Femoropopliteal Lesions.
Laird JA; Schneider PA; Jaff MR; Brodmann M; Zeller T; Metzger DC; Krishnan P; Scheinert D; Micari A; Wang H; Masters M; Tepe G
Circ Cardiovasc Interv; 2019 Jun; 12(6):e007702. PubMed ID: 31195825
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
